Abstract Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
signaling is one of the most important intracellular pathways, which can be considered as a …

Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …

Despite development of novel agents targeting oncogenic pathways, matching targeted
therapies to the genetic status of individual tumors is proving to be a daunting task for …

The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular
processes and is frequently altered in cancer, contributing to tumor growth and survival …

The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin
(mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and …

Protein levels and function are poorly predicted by genomic and transcriptomic analysis of
patient tumours. Therefore, direct study of the functional proteome has the potential to …

Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast
cancer. However, clinical results of single-agent PI3K inhibitors have been modest to date. A …

Over the last few decades, study of cancer in mouse models has gained popularity.
Sophisticated genetic manipulation technologies and commercialization of these murine …

Unsustained enzyme inhibition is a barrier to targeted therapy for cancer. Here, resistance to
a class I PI3K inhibitor in a model of metastatic breast cancer driven by PI3K and MYC was …